Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.TO)

VRX.TO on Toronto Stock Exchange

18.80CAD
--
Change (% chg)

-- (--)
Prev Close
$18.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,399,100
52-wk High
$25.22
52-wk Low
$11.20

Chart for

About

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment,... (more)

Overall

Beta: -0.46
Market Cap(Mil.): $5,117.00
Shares Outstanding(Mil.): 347.33
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

BRIEF-Valeant announces pricing of private offering of add-on secured notes

* Valeant announces pricing of private offering of add-on secured notes

Nov 14 2017

BRIEF-Valeant announces launch of private offering of add-on secured notes

* Valeant announces launch of private offering of add-on secured notes

Nov 13 2017

BRIEF-Valeant Pharmaceuticals amends existing credit agreement

Nov 9 Valeant Pharmaceuticals International Inc :

Nov 09 2017

CANADA STOCKS-TSX adds to record highs as Valeant shares surge

TORONTO, Nov 7 Canada's main stock index added to its record highs on Tuesday, boosted by a jump in the shares of Valeant Pharmaceuticals International Inc after the company's earnings beat estimates, while some energy shares also climbed.

Nov 07 2017

CANADA STOCKS-TSX adds to record highs as Valeant, energy climb

TORONTO, Nov 7 Canada's main stock index added to its record highs on Tuesday, boosted by a jump in the shares of Valeant Pharmaceuticals International Inc after the company's quarterly profit beat estimates, while energy shares also climbed.

Nov 07 2017

Valeant profit beats forecasts on Bausch & Lomb strength

Valeant Pharmaceuticals International Inc reported a better-than-expected quarterly profit on strength in its Bausch and Lomb eye care business, sending its shares up more than 15 percent.

Nov 07 2017

UPDATE 3-Valeant profit beats forecasts on Bausch & Lomb strength

Nov 7 Valeant Pharmaceuticals International Inc reported a better-than-expected quarterly profit on strength in its Bausch and Lomb eye care business, sending its shares up more than 15 percent.

Nov 07 2017

BRIEF-Valeant announces Q3 revenue of $2.22 billion

* Q3 revenue $2.219 billion versus I/B/E/S view $2.15 billion

Nov 07 2017

Drugmaker Valeant's revenue falls 10.5 pct

Nov 7 Canada's Valeant Pharmaceuticals International Inc reported a 10.5 percent fall in quarterly revenue on Tuesday, hurt by declining sales in its branded drugs division.

Nov 07 2017

Competitors

Earnings vs. Estimates